Preclinical research published online ahead of print in the Journal of Vascular and Interventional Radiology (JVIR) in July shows that combretastatin A4 is a stronger inhibitor of the smooth muscle cell cycle than sirolimus or paclitaxel. Thus, it may represent an alternative coating for drug-eluting stents and balloons in atherosclerotic luminal stenosis, the investigators write.
Results from the 9th Annual Survey on Observational Research conducted by Continuum Clinical suggest that the pharmaceutical, biotech, and medical device industries are aware of the benefits of observational research in better understanding the real world value of their products. However, they also show that there is continued need to improve the design and implementation of the studies.
Guerbet has announced entering into a definitive agreement under which it will acquire Mallinckrodt’s contrast media and delivery systems business in its entirety for approximately US$270 million. With this acquisition, Guerbet aims to create a new global leader in medical imaging.
Two new studies presented at the Society of NeuroInterventional Surgery 12th Annual Meeting in San Francisco, USA, report that Mobile Stroke Treatment Units (MSTUs) can significantly reduce the time it takes to diagnose and treat patients for stroke, greatly improving survival rates and enhancing a patient’s chance of recovery.
The US Food and Drug Administration (FDA) has consented to the initiation of the clinical study for the new Gore Excluder conformable abdominal aortic aneurysm endoprosthesis, and the Japanese clinical trial notification for the new device was accepted by Japan’s Pharmaceuticals and Medical Devices Agency.
Gore is making available an educational compendium of presentations and discussions from the inaugural Gore-sponsored Surgical Bypass Summit to promote knowledge sharing around this topic. The content is now available at www.surgicalbypass.com. The event co-chairs, Richard Neville and Russell Samson, along with a global group of vascular surgeons, are leading an effort to revisit treatment paradigms for the continual improvement of patient care, an initiative which was at the front of mind at the 2015 Society for Vascular Surgery Annual Meeting (17–20 June, Chicago, USA).
Medtronic has announced a financial investment in Arsenal AAA, a wholly owned subsidiary of Arsenal Medical. In return, Medtronic has received an option to acquire Arsenal AAA after the company achieves certain milestones. Financial terms of the investment were not disclosed.
Vascular Flow Technologies has announced a new observational registry for Spiral Flow arteriovenous (AV) grafts in haemodialysis access that will be conducted by the Society for Vascular Surgery Patient Safety Organization (SVS PSO) as part of their ongoing Vascular Quality Initiative. The inititative is designed to improve vascular health care and provides an opportunity for individual providers, hospitals, and regional quality improvement groups to collect and analyse clinical data in an effort to improve patient care.
Updates from the Gore Global Registry for Endovascular Aortic Treatment (GREAT) will be presented at the Society for Vascular Surgery Annual Meeting (17–20 June, Chicago, USA). To date, more than 3,000 patients have been enrolled in GREAT, the largest real world endovascular registry which is actively monitored and audited to ensure data reported is accurate.
Terumo Interventional Systems had introduced the Misago RX self-expanding peripheral stent to the US market at the 2015 Society for Vascular Surgery Annual Meeting (SVS; 17–20 June, Chicago, USA).
Vascular Solutions has launched two new versions of its Turnpike catheters for use in complex coronary and peripheral interventions. The original version of Turnpike was introduced in January 2015, and now Vascular Solutions has added the Turnpike Spiral and Turnpike Gold versions to the product line.
Selected for nearly one of every two endovascular abdominal aortic aneurysm (AAA) repairs globally, the Endurant AAA stent graft system from Medtronic maintained durable, consistent and proven outcomes through five years of follow-up in the company’s US clinical study of the implantable medical device, according to new clinical data presented at the Society for Vascular Surgery’s Annual Meeting (17–20 June, Chicago, USA).
The US Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for Surgical Specialties’ BioSentry track sealant system under the Medicare hospital outpatient prospective payment system. This important approval removes a potential barrier to patient access to this new medical device, which offers the potential to improve outcomes for patients undergoing a percutaneous transthoracic lung biopsy.
Thirty-day results from the EVAS FORWARD-IDE study show 100% procedural technical success with few device-related serious adverse events with the Nellix EndoVascular Aneurysm Sealing (EVAS; Endologix) in abdominal aortic aneurysm patients, and a 6% incidence of any endoleak on the one-month computed tomography angiographic (CTA) scan. Data from the investigational device exemption investigation were presented at the Society for Vascular Surgery’s Annual Meeting in Chicago, USA.
Spectranetics has received US Food and Drug Administration 510(k) clearance for the AngioSculpt percutaneous transluminal angioplasty (PTA) scoring balloon catheter in 7mm and 8mm diameter balloon sizes, designed to treat the narrowing of the native or synthetic fistula.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos